The Domestic contract manufacturers industry on FinBizNet covers 4 listed companies, with broker-view summaries, sub-industry segmentation, latest quarterly results and peer comparisons for each constituent.
| Listed companies | 4 |
|---|---|
| Combined market cap | ₹18,641 Cr |
| Median P/E (profitable companies) | 34.4 |
| Median return on equity | 13.1% |
| Companies with latest quarterly results | 3 of 4 |
| Company | Market Cap | P/E | ROE | Quarterly Revenue | Quarterly Net Profit | Quarter |
|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limited | ₹10,512 Cr | 41.2 | 8.0% | ₹1,167 Cr | ₹101 Cr | Q1 FY27 |
| INNOVA CAPTAB LIMITED | ₹5,712 Cr | 40.5 | 14.0% | ₹471 Cr | ₹44 Cr | Q1 FY27 |
| Windlas Biotech Ltd | ₹1,821 Cr | 28.3 | 12.2% | ₹248 Cr | ₹18 Cr | Q1 FY27 |
| Influx Healthtech Limited | ₹596 Cr | 27.5 | 20.4% | — | — | — |
Market data from the FinBizNet stock universe; quarterly figures in ₹ crore, parsed from each company's exchange filing (XBRL).
FinBizNet tracks 4 listed companies in the Domestic contract manufacturers industry: Akums Drugs and Pharmaceuticals Limited, INNOVA CAPTAB LIMITED, Windlas Biotech Ltd, Influx Healthtech Limited.
By market capitalisation, the largest Domestic contract manufacturers companies are Akums Drugs and Pharmaceuticals Limited (₹10,512 Cr), INNOVA CAPTAB LIMITED (₹5,712 Cr), Windlas Biotech Ltd (₹1,821 Cr), Influx Healthtech Limited (₹596 Cr).
The 4 Domestic contract manufacturers companies tracked on FinBizNet have a combined market capitalisation of about ₹18,641 Cr.
The median price-to-earnings ratio across 4 profitable Domestic contract manufacturers companies is 34.4, and the median return on equity across the industry is 13.1%. Medians are shown for context only.
FinBizNet aggregates broker research, sub-industry breakdowns, quarterly results and peer-stock comparisons across the Domestic contract manufacturers industry.